A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

University of California San Diego researchers have identified a U-shaped association between high-density lipoprotein (HDL) ...

Volunteers are needed to help run a leading sight loss charity support group, which supports people affected by macular ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration ... the sound of a voice to recognise who was there.

In the last 20 years, there have been rapid advances in the treatment options for myopic ... it is possible that patients with myopic macular degeneration complicated by CNV may benefit from ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

Currently, there is no cure for dry AMD, but two therapies appear effective ... With a better understanding of how age-related macular degeneration (AMD) occurs, researchers have been able to develop ...